Global Scleroderma Market
Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027
January 30, 2024 20:25 ET | Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global scleroderma market is poised for...
APIE-logo.png
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
August 30, 2022 08:00 ET | APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
APIE-logo.png
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
August 02, 2022 10:15 ET | APIE Therapeutics
Cary, NC, Aug. 02, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ),...
APIE-logo.png
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
January 12, 2022 07:30 ET | APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
logo.png
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
November 09, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
logo.png
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
October 21, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...
logo.png
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
September 08, 2020 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...
logo.png
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
July 29, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on hand of...
logo.png
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
June 22, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...
logo.png
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
June 01, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...